Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CARDIOTOXICITY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CARDIOTOXICITY TREATMENT MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY BASED MODELLING
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CARDIOTOXICITY TREATMENT MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES MODEL
6 EPIDEMIOLOGY
7 INDUSTRY INSIGHTS
8 REGULATORY FRAMEWORK
9 PIPELINE ANALYSIS
9.1 PHASE III CANDIDATES
9.2 PHASE II CANDIDATES
9.3 PHASE I CANDIDATES
9.4 OTHERS (PRE-CLINICAL AND RESEARCH)
10 GLOBAL CARDIOTOXICITY TREATMENT MARKET, BY CAUSE
10.1 OVERVIEW
10.2 CHEMOTHERAPY INDUCED CARDIOTOXICITY
10.2.1 ANTHRACYCLINES
10.2.2 NON-ANTHRACYCLINES
10.3 NON-CHEMOTHERAPY CARDIOTOXICITY
11 GLOBAL CARDIOTOXICITY TREATMENT MARKET, BY TYPE
11.1 OVERVIEW
11.2 DIAGNOSIS
11.2.1 IN VIVO DIAGNOSIS
11.2.1.1. ELECTROCARDIOGRAM
11.2.1.2. ECHOCARDIOGRAM
11.2.1.3. CARDIAC BIOPSY
11.2.1.4. MULTI GATED ACQUISITION (MUGA) SCAN
11.2.1.5. OTHERS
11.2.2 IN VITRO DIAGNOSIS
11.2.2.1. INSTRUMENTS
11.2.2.2. ASSAYS & REAGENTS
11.2.2.2.1. HERG ASSAYS
11.2.2.2.2. QT PROLONGATION ASSAYS
11.2.2.2.3. CALCIUM TRANSIENT ASSAY
11.2.2.2.4. COMPREHENSIVE IN VITRO PROARRHYTMIA ASSAY (CIPA)
11.2.2.2.5. CARDIAC BIOMARKER
11.2.2.2.5.1 TROPININ I & T
11.2.2.2.5.2 B-TYPE NATRIURETIC PEPTIDE (BNP)
11.2.2.2.6. OTHERS
11.2.2.3. OTHERS
11.3 TREATMENT
11.3.1 DEXRAZOXANE HYDROCHLORIDE
11.3.2 ACE INHIBITORS
11.3.2.1. BENAZEPRIL
11.3.2.1.1. MARKET VALUE (USD MN)
11.3.2.1.2. MARKET VOLUME (SU)
11.3.2.1.3. AVERAGE SELLING PRICE (USD)
11.3.2.2. CAPTOPRIL
11.3.2.2.1. MARKET VALUE (USD MN)
11.3.2.2.2. MARKET VOLUME (SU)
11.3.2.2.3. AVERAGE SELLING PRICE (USD)
11.3.2.3. ENALAPRIL
11.3.2.3.1. MARKET VALUE (USD MN)
11.3.2.3.2. MARKET VOLUME (SU)
11.3.2.3.3. AVERAGE SELLING PRICE (USD)
11.3.2.4. LISINOPRIL
11.3.2.4.1. MARKET VALUE (USD MN)
11.3.2.4.2. MARKET VOLUME (SU)
11.3.2.4.3. AVERAGE SELLING PRICE (USD)
11.3.2.5. OTHERS
11.3.3 ANGIOTENSIN II RECEPTOR ANTAGONISTS (ARBS)
11.3.3.1. CANDESARTAN CILEXETIL
11.3.3.1.1. MARKET VALUE (USD MN)
11.3.3.1.2. MARKET VOLUME (SU)
11.3.3.1.3. AVERAGE SELLING PRICE (USD)
11.3.3.2. EPROSARTAN MESYLATE
11.3.3.2.1. MARKET VALUE (USD MN)
11.3.3.2.2. MARKET VOLUME (SU)
11.3.3.2.3. AVERAGE SELLING PRICE (USD)
11.3.3.3. IRBESARTAN
11.3.3.3.1. MARKET VALUE (USD MN)
11.3.3.3.2. MARKET VOLUME (SU)
11.3.3.3.3. AVERAGE SELLING PRICE (USD)
11.3.3.4. LOSARTAN
11.3.3.4.1. MARKET VALUE (USD MN)
11.3.3.4.2. MARKET VOLUME (SU)
11.3.3.4.3. AVERAGE SELLING PRICE (USD)
11.3.3.5. OTHERS
11.3.4 BETA BLOCKERS
11.3.4.1. ACEBUTOLOL
11.3.4.1.1. MARKET VALUE (USD MN)
11.3.4.1.2. MARKET VOLUME (SU)
11.3.4.1.3. AVERAGE SELLING PRICE (USD)
11.3.4.2. BISOPROLOL
11.3.4.2.1. MARKET VALUE (USD MN)
11.3.4.2.2. MARKET VOLUME (SU)
11.3.4.2.3. AVERAGE SELLING PRICE (USD)
11.3.4.3. CARVEDILOL
11.3.4.3.1. MARKET VALUE (USD MN)
11.3.4.3.2. MARKET VOLUME (SU)
11.3.4.3.3. AVERAGE SELLING PRICE (USD)
11.3.4.4. METOPROLOL
11.3.4.4.1. MARKET VALUE (USD MN)
11.3.4.4.2. MARKET VOLUME (SU)
11.3.4.4.3. AVERAGE SELLING PRICE (USD)
11.3.4.5. OTHERS
11.3.5 CALCIUM CHANNEL BLOCKERS
11.3.5.1. AMLODIPINE
11.3.5.1.1. MARKET VALUE (USD MN)
11.3.5.1.2. MARKET VOLUME (SU)
11.3.5.1.3. AVERAGE SELLING PRICE (USD)
11.3.5.2. FELODIPINE
11.3.5.3. NICARDIPINE
11.3.5.3.1. MARKET VALUE (USD MN)
11.3.5.3.2. MARKET VOLUME (SU)
11.3.5.3.3. AVERAGE SELLING PRICE (USD)
11.3.5.4. NIFEDIPINE
11.3.5.4.1. MARKET VALUE (USD MN)
11.3.5.4.2. MARKET VOLUME (SU)
11.3.5.4.3. AVERAGE SELLING PRICE (USD)
11.3.5.5. VERAPAMIL
11.3.5.5.1. MARKET VALUE (USD MN)
11.3.5.5.2. MARKET VOLUME (SU)
11.3.5.5.3. AVERAGE SELLING PRICE (USD)
11.3.5.6. OTHERS
11.3.6 DIURETICS
11.3.6.1. AMILORIDE
11.3.6.1.1. MARKET VALUE (USD MN)
11.3.6.1.2. MARKET VOLUME (SU)
11.3.6.1.3. AVERAGE SELLING PRICE (USD)
11.3.6.2. BUMETANIDE
11.3.6.2.1. MARKET VALUE (USD MN)
11.3.6.2.2. MARKET VOLUME (SU)
11.3.6.2.3. AVERAGE SELLING PRICE (USD)
11.3.6.3. FUROSEMIDE
11.3.6.3.1. MARKET VALUE (USD MN)
11.3.6.3.2. MARKET VOLUME (SU)
11.3.6.3.3. AVERAGE SELLING PRICE (USD)
11.3.6.4. OTHERS
11.3.7 OTHERS
12 GLOBAL CARDIOTOXICITY TREATMENT MARKET, BY STAGES
12.1 OVERVIEW
12.2 ACUTE CARDIOTOXICITY
12.2.1 ECG CHANGES
12.2.2 ARRYTHMIAS
12.3 SUBACUTE CARDIOTOXICITY
12.3.1 PERICARDITIS
12.3.2 MYOCARDITIS
12.4 CHRONIC CARDIOTOXICITY
12.4.1 CONTRACTILE DYSFUNCTION
12.4.2 HEART FAILURE
13 GLOBAL CARDIOTOXICITY TREATMENT MARKET, BY ROUT OF ADMINISTRATION
13.1 OVERVIEW
13.2 ORAL
13.2.1 TABLETS
13.2.2 CAPSULES
13.2.3 OTHERS
13.3 PARENTERAL
13.3.1 INTRAVENOUS
13.3.2 SUBCUTANEOUS
13.3.3 OTHERS
13.4 OTHERS
14 GLOBAL CARDIOTOXICITY TREATMENT MARKET, BY AGE GROUP
14.1 OVERVIEW
14.2 PEDIATRICS
14.3 ADULTS
15 GLOBAL CARDIOTOXICITY TREATMENT MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 GLOBAL CARDIOTOXICITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 PHARMACIES
16.4 OTHERS
17 GLOBAL CARDIOTOXICITY TREATMENT MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL CARDIOTOXICITY TREATMENT MARKET, BY GEOGRAPHY
18.1 GLOBAL CARDIOTOXICITY TREATMENT MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
18.1.1 NORTH AMERICA
18.1.1.1. U.S.
18.1.1.2. CANADA
18.1.1.3. MEXICO
18.1.2 EUROPE
18.1.2.1. GERMANY
18.1.2.2. FRANCE
18.1.2.3. U.K.
18.1.2.4. HUNGARY
18.1.2.5. LITHUANIA
18.1.2.6. AUSTRIA
18.1.2.7. IRELAND
18.1.2.8. NORWAY
18.1.2.9. POLAND
18.1.2.10. ITALY
18.1.2.11. SPAIN
18.1.2.12. RUSSIA
18.1.2.13. TURKEY
18.1.2.14. NETHERLANDS
18.1.2.15. SWITZERLAND
18.1.2.16. REST OF EUROPE
18.1.3 ASIA-PACIFIC
18.1.3.1. JAPAN
18.1.3.2. CHINA
18.1.3.3. SOUTH KOREA
18.1.3.4. INDIA
18.1.3.5. AUSTRALIA
18.1.3.6. SINGAPORE
18.1.3.7. THAILAND
18.1.3.8. MALAYSIA
18.1.3.9. INDONESIA
18.1.3.10. PHILIPPINES
18.1.3.11. VIETNAM
18.1.3.12. REST OF ASIA-PACIFIC
18.1.4 SOUTH AMERICA
18.1.4.1. BRAZIL
18.1.4.2. ARGENTINA
18.1.4.3. PERU
18.1.4.4. REST OF SOUTH AMERICA
18.1.5 MIDDLE EAST AND AFRICA
18.1.5.1. SOUTH AFRICA
18.1.5.2. SAUDI ARABIA
18.1.5.3. UAE
18.1.5.4. EGYPT
18.1.5.5. KUWAIT
18.1.5.6. ISRAEL
18.1.5.7. REST OF MIDDLE EAST AND AFRICA
18.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
19 GLOBAL CARDIOTOXICITY TREATMENT MARKET, SWOT AND DBMR ANALYSIS
20 GLOBAL CARDIOTOXICITY TREATMENT MARKET, COMPANY PROFILE
20.1 DIAGNOSIS
20.1.1 CREATIVE BIOARRAY
20.1.1.1. COMPANY OVERVIEW
20.1.1.2. REVENUE ANALYSIS
20.1.1.3. GEOGRAPHIC PRESENCE
20.1.1.4. PRODUCT PORTFOLIO
20.1.1.5. RECENT DEVELOPMENTS
20.1.2 MOLECULAR DEVICES, LLC.
20.1.2.1. COMPANY OVERVIEW
20.1.2.2. REVENUE ANALYSIS
20.1.2.3. GEOGRAPHIC PRESENCE
20.1.2.4. PRODUCT PORTFOLIO
20.1.2.5. RECENT DEVELOPMENTS
20.1.3 MERCK KGAA
20.1.3.1. COMPANY OVERVIEW
20.1.3.2. REVENUE ANALYSIS
20.1.3.3. GEOGRAPHIC PRESENCE
20.1.3.4. PRODUCT PORTFOLIO
20.1.3.5. RECENT DEVELOPMENTS
20.1.4 AGILENT TECHNOLOGIES, INC.
20.1.4.1. COMPANY OVERVIEW
20.1.4.2. REVENUE ANALYSIS
20.1.4.3. GEOGRAPHIC PRESENCE
20.1.4.4. PRODUCT PORTFOLIO
20.1.4.5. RECENT DEVELOPMENTS
20.1.5 HAMAMATSU PHOTONICS K.K.
20.1.5.1. COMPANY OVERVIEW
20.1.5.2. REVENUE ANALYSIS
20.1.5.3. GEOGRAPHIC PRESENCE
20.1.5.4. PRODUCT PORTFOLIO
20.1.5.5. RECENT DEVELOPMENTS
20.1.6 CREATIVE BIOLABS.
20.1.6.1. COMPANY OVERVIEW
20.1.6.2. REVENUE ANALYSIS
20.1.6.3. GEOGRAPHIC PRESENCE
20.1.6.4. PRODUCT PORTFOLIO
20.1.6.5. RECENT DEVELOPMENTS
20.1.7 EUROFINS DISCOVERX PRODUCTS.
20.1.7.1. COMPANY OVERVIEW
20.1.7.2. REVENUE ANALYSIS
20.1.7.3. GEOGRAPHIC PRESENCE
20.1.7.4. PRODUCT PORTFOLIO
20.1.7.5. RECENT DEVELOPMENTS
20.1.8 CREATIVE DIAGNOSTICS
20.1.8.1. COMPANY OVERVIEW
20.1.8.2. REVENUE ANALYSIS
20.1.8.3. GEOGRAPHIC PRESENCE
20.1.8.4. PRODUCT PORTFOLIO
20.1.8.5. RECENT DEVELOPMENTS
20.1.9 LIFE DIAGNOSTICS
20.1.9.1. COMPANY OVERVIEW
20.1.9.2. REVENUE ANALYSIS
20.1.9.3. GEOGRAPHIC PRESENCE
20.1.9.4. PRODUCT PORTFOLIO
20.1.9.5. RECENT DEVELOPMENTS
20.1.10 HYTEST LTD.
20.1.10.1. COMPANY OVERVIEW
20.1.10.2. REVENUE ANALYSIS
20.1.10.3. GEOGRAPHIC PRESENCE
20.1.10.4. PRODUCT PORTFOLIO
20.1.10.5. RECENT DEVELOPMENTS
20.2 THERAPEUTICS
20.2.1 PFIZER INC.
20.2.1.1. COMPANY OVERVIEW
20.2.1.2. REVENUE ANALYSIS
20.2.1.3. GEOGRAPHIC PRESENCE
20.2.1.4. PRODUCT PORTFOLIO
20.2.1.5. RECENT DEVELOPMENTS
20.2.2 HIKMA PHARMACEUTICALS PLC
20.2.2.1. COMPANY OVERVIEW
20.2.2.2. REVENUE ANALYSIS
20.2.2.3. GEOGRAPHIC PRESENCE
20.2.2.4. PRODUCT PORTFOLIO
20.2.2.5. RECENT DEVELOPMENTS
20.2.3 AUROMEDICS PHARMA LLC PHARMA LLC
20.2.3.1. COMPANY OVERVIEW
20.2.3.2. REVENUE ANALYSIS
20.2.3.3. GEOGRAPHIC PRESENCE
20.2.3.4. PRODUCT PORTFOLIO
20.2.3.5. RECENT DEVELOPMENTS
20.2.4 ASTRAZENECA
20.2.4.1. COMPANY OVERVIEW
20.2.4.2. REVENUE ANALYSIS
20.2.4.3. GEOGRAPHIC PRESENCE
20.2.4.4. PRODUCT PORTFOLIO
20.2.4.5. RECENT DEVELOPMENTS
20.2.5 BRISTOL-MYERS SQUIBB
20.2.5.1. COMPANY OVERVIEW
20.2.5.2. REVENUE ANALYSIS
20.2.5.3. GEOGRAPHIC PRESENCE
20.2.5.4. PRODUCT PORTFOLIO
20.2.5.5. RECENT DEVELOPMENTS
20.2.6 NOVARTIS AG
20.2.6.1. COMPANY OVERVIEW
20.2.6.2. REVENUE ANALYSIS
20.2.6.3. GEOGRAPHIC PRESENCE
20.2.6.4. PRODUCT PORTFOLIO
20.2.6.5. RECENT DEVELOPMENTS
20.2.7 SANOFI
20.2.7.1. COMPANY OVERVIEW
20.2.7.2. REVENUE ANALYSIS
20.2.7.3. GEOGRAPHIC PRESENCE
20.2.7.4. PRODUCT PORTFOLIO
20.2.7.5. RECENT DEVELOPMENTS
20.2.8 BAYER AG
20.2.8.1. COMPANY OVERVIEW
20.2.8.2. REVENUE ANALYSIS
20.2.8.3. GEOGRAPHIC PRESENCE
20.2.8.4. PRODUCT PORTFOLIO
20.2.8.5. RECENT DEVELOPMENTS
20.2.9 ALLERGAN ( A PART OF ABBVIE INC.)
20.2.9.1. COMPANY OVERVIEW
20.2.9.2. REVENUE ANALYSIS
20.2.9.3. GEOGRAPHIC PRESENCE
20.2.9.4. PRODUCT PORTFOLIO
20.2.9.5. RECENT DEVELOPMENTS
20.2.10 TEVA PHARMACEUTICAL INDUSTRIES LTD.
20.2.10.1. COMPANY OVERVIEW
20.2.10.2. REVENUE ANALYSIS
20.2.10.3. GEOGRAPHIC PRESENCE
20.2.10.4. PRODUCT PORTFOLIO
20.2.10.5. RECENT DEVELOPMENTS
20.2.11 MERCK & CO.
20.2.11.1. COMPANY OVERVIEW
20.2.11.2. REVENUE ANALYSIS
20.2.11.3. GEOGRAPHIC PRESENCE
20.2.11.4. PRODUCT PORTFOLIO
20.2.11.5. RECENT DEVELOPMENTS
20.2.12 UCB, INC.
20.2.12.1. COMPANY OVERVIEW
20.2.12.2. REVENUE ANALYSIS
20.2.12.3. GEOGRAPHIC PRESENCE
20.2.12.4. PRODUCT PORTFOLIO
20.2.12.5. RECENT DEVELOPMENTS
20.2.13 VIATRIS INC.
20.2.13.1. COMPANY OVERVIEW
20.2.13.2. REVENUE ANALYSIS
20.2.13.3. GEOGRAPHIC PRESENCE
20.2.13.4. PRODUCT PORTFOLIO
20.2.13.5. RECENT DEVELOPMENTS
20.2.14 F. HOFFMANN-LA ROCHE LTD
20.2.14.1. COMPANY OVERVIEW
20.2.14.2. REVENUE ANALYSIS
20.2.14.3. GEOGRAPHIC PRESENCE
20.2.14.4. PRODUCT PORTFOLIO
20.2.14.5. RECENT DEVELOPMENTS
20.2.15 ELI LILLY AND COMPANY
20.2.15.1. COMPANY OVERVIEW
20.2.15.2. REVENUE ANALYSIS
20.2.15.3. GEOGRAPHIC PRESENCE
20.2.15.4. PRODUCT PORTFOLIO
20.2.15.5. RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
24 ABOUT DATA BRIDGE MARKET RESEARCH
